RayKnowChina Research Map
Shortlist0

Shenzhen University

深圳大学

ShenzhenUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.5%Leads under 1 in 100 of China's research papers on NPC

Led 11 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
11
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 3320242025: 112025
ThemesRecurrent / metastatic diseaseImaging & AIEBV & screening

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Shenzhen Second People's Hospital4
  2. Third Affiliated Hospital of Shenzhen University Counted in the group total2
  3. Shenzhen University General Hospital Counted in the group total1
  4. Shenzhen University First Affiliated Hospital1
  5. Sixth Affiliated Hospital of Shenzhen University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.1%Leads under 1 in 100 of China's research papers on ESCC

Led 3 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.07%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 002025

Hospitals counted here

  1. Shenzhen Second People's Hospital Counted in the group total2
  2. Shenzhen University General Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
0.2%Leads under 1 in 100 of China's research papers on HCC

Led 37 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
1
Research papers it led
37
Trials it led
1
Share of China's trials
0.07%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025
ThemesImaging, AI & early detectionRecurrence & prognosisImmunotherapy & targeted drugs

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Shenzhen Second People's Hospital17
  2. Shenzhen University General Hospital6
  3. South China Hospital Counted in the group total5
  4. International Cancer Center Counted in the group total1
  5. Third Affiliated Hospital of Shenzhen University Counted in the group total1
  6. South China Hospital, Shenzhen University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
0.3%Leads under 1 in 100 of China's research papers on Stomach cancer

Led 33 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
1
Research papers it led
33
Trials it led
1
Share of China's trials
0.07%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
ThemesEarly detection & endoscopyImaging & AISurgery

Hospitals counted here

  1. Shenzhen Second People's Hospital14
  2. South China Hospital Counted in the group total5
  3. International Cancer Center Counted in the group total3
  4. Shenzhen University General Hospital2
  5. Sixth Affiliated Hospital of Shenzhen University1
  6. Carson International Cancer Center1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
0.7%Leads under 1 in 100 of China's research papers on Retinoblastoma

Led 2 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Shenzhen Second People's Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
0.3%Leads under 1 in 100 of China's research papers on Osteosarcoma

Led 6 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 332025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Shenzhen Second People's Hospital3
  2. Shenzhen University General Hospital2
  3. Third Affiliated Hospital of Shenzhen University1
  4. Third Affiliated Hospital, Shenzhen University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.09%Leads under 1 in 100 of China's research papers on Neuroblastoma New since 2021

Led 1 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
1
Share of China's trials
2.4%
Share of the world's papers
0.02%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Shenzhen University General Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
0.3%Leads under 1 in 100 of China's research papers on Myeloma

Led 5 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
4
Share of China's trials
0.8%
Share of the world's papers
0.05%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 112025
ThemesCAR-T & cell therapyRelapse & resistanceDrug combinations

Hospitals counted here

  1. Shenzhen Second People's Hospital2
  2. South China Hospital Counted in the group total2
  3. Shenzhen University General Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Integrated clinical and single-cell profiling of BCMA CAR-T therapy in relapsed/refractory multiple myeloma.2025Journal of translational medicineFree full text
  2. Immunoglobulin heavy chain gene rearrangement in heavy chain deposition disease suggests it is a plasma cell disease: a case report.2022The Journal of international medical researchFree full text
  3. Identification of COQ2 as a regulator of proliferation and lipid peroxidation through genome-scale CRISPR-Cas9 screening in myeloma cells.2024British journal of haematology
  4. Gigantic Flaming Cells in an IgA-MGUS patient.2023Annales de biologie clinique
  5. A Patient with Pure Erythroid Leukemia with Leukemic Cells Mimicking Myeloma Cells.2022Turkish journal of haematology : official journal of Turkish Society of HaematologyFree full text
Trials on ClinicalTrials.gov6
  1. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple MyelomaRecruitingNCT06049290Study sitePhase 1/Phase 2Start 2023-10
  2. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingNCT05020236Study sitePhase 3Start 2021-10
  3. BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple MyelomaStatus unknownNCT06644443Lead sponsorPhase 1/Phase 2Start 2023-07
  4. B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple MyelomaStatus unknownNCT05150522Lead sponsorPhase 1/Phase 2Start 2021-07
  5. Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple MyelomaStatus unknownNCT03767725Lead sponsorPhase 1Start 2018-06
  6. T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing MalignanciesStatus unknownNCT02457650Lead sponsorPhase 1Start 2015-04

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
0.9%Leads under 1 in 100 of China's research papers on B-ALL New since 2021

Led 2 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
1
Research papers it led
2
Trials it led
4
Share of China's trials
1.6%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025
ThemesChildrenCAR-T & cell therapyPhiladelphia chromosome & genetics

Hospitals counted here

  1. Second Affiliated Hospital of Shenzhen University1
  2. South China Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Beta thalassaemia

β 地中海贫血
0.6%Leads under 1 in 100 of China's research papers on Beta thalassaemia ▼ from 1.2%

Led 2 of 312 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.9%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Shenzhen Second People's Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Wilson disease

肝豆状核变性(Wilson 病)
1.5%Leads about 1 in 67 of China's research papers on Wilson disease New since 2021

Led 3 of 201 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.5%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 112025
ThemesGenetics (ATP7B)Liver disease & transplantChildren

Hospitals counted here

  1. Shenzhen Second People's Hospital3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
0.8%Leads under 1 in 100 of China's research papers on Anti-NMDA receptor encephalitis New since 2021

Led 2 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Third Affiliated Hospital of Shenzhen University1
  2. Shenzhen Second People's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led2
  1. Clinical analysis of a patient simultaneously positive for antibodies of myelin oligodendrocyte glycoprotein and anti-N-methyl-D-aspartate receptor: A case report.2021Medicine
  2. HSV encephalitis triggered anti-NMDAR encephalitis: a case report.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.2%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis New since 2021

Led 2 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.05%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. South China Hospital1
  2. International Cancer Center1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
0.3%Leads under 1 in 100 of China's research papers on Amyotrophic lateral sclerosis

Led 2 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.03%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Children's Hospital, Shenzhen University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led2
  1. Evolving markers in amyotrophic lateral sclerosis.2023Advances in clinical chemistry
  2. Polygenic associations and causal inferences between serum immunoglobulins and amyotrophic lateral sclerosis.2021Clinica chimica acta; international journal of clinical chemistry

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
0.4%Leads under 1 in 100 of China's research papers on IgA nephropathy

Led 3 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
2
Share of China's trials
1.7%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Shenzhen Second People's Hospital3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov